VBLT logo

Vascular Biogenics Ltd

VBLT

VBLT: Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

more

Show VBLT Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of VBLT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard
Insider Trading

Quarterly net insider trading by VBLT's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Motile sperm domain containing protein 2 antibodies and methods of use thereof Jul. 11, 2023
  • Patent Title: Treatment methods using adenovirus Apr. 26, 2022
  • Patent Title: Methods of inducing responsiveness to anti-angiogenic agent Dec. 07, 2021
  • Patent Title: Oxidized lipids and methods of use thereof Nov. 05, 2019
  • Patent Title: Methods of inducing responsiveness to anti-angiogenic agent Aug. 20, 2019
  • Patent Title: Compositions and methods for treating glioblastoma gbm Aug. 06, 2019
  • Patent Title: Oxidized lipids and treatment or prevention of fibrosis Feb. 19, 2019
  • Patent Title: Oxidized lipids and treatment or prevention of fibrosis Jul. 17, 2018
  • Patent Title: High-purity phospholipids May. 15, 2018
  • Patent Title: Oxidized lipids Sep. 26, 2017
  • Patent Title: Methods of inducing responsiveness to anti-angiogenic agent Jun. 20, 2017
  • Patent Title: Methods for use of a specific anti-angiogenic adenoviral agent Feb. 14, 2017
  • Patent Title: Endothelial cell-specific polynucleotides and use thereof Aug. 02, 2016
  • Patent Title: Formulations and dosage forms of oxidized phospholipids Feb. 09, 2016
  • Patent Title: Oxidized lipid compounds and uses thereof Dec. 08, 2015
  • Patent Title: Fas-chimera adenovirus vector Dec. 01, 2015
  • Patent Title: High-purity phospholipids Apr. 14, 2015
  • Patent Title: Oxidized thiophospholipid compounds and uses thereof Apr. 07, 2015
  • Patent Title: Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy Dec. 23, 2014
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same Oct. 14, 2014
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same Oct. 14, 2014
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same Sep. 30, 2014
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Sep. 16, 2014
  • Patent Title: Process for the preparation of oxidized phospholipids Aug. 12, 2014
  • Patent Title: Process for the preparation of oxidized phospholipids Jun. 24, 2014
  • Patent Title: High-purity phospholipids Oct. 29, 2013
  • Patent Title: Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis Oct. 22, 2013
  • Patent Title: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders Aug. 06, 2013
  • Patent Title: Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy Apr. 09, 2013
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Jun. 26, 2012
  • Patent Title: Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis Apr. 17, 2012
  • Patent Title: Process for the preparation of oxidized phospholipids Feb. 28, 2012
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Dec. 06, 2011
  • Patent Title: Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Oct. 18, 2011
  • Patent Title: Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy Aug. 02, 2011
  • Patent Title: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders Jul. 05, 2011
  • Patent Title: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders Mar. 08, 2011
  • Patent Title: Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis Feb. 22, 2011
  • Patent Title: Process for the preparation of oxidized phospholipids Oct. 05, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of VBLT in WallStreetBets Daily Discussion

VBLT News

Recent insights relating to VBLT

CNBC Recommendations

Recent picks made for VBLT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VBLT

Corporate Flights

Flights by private jets registered to VBLT